The TRAR gene classifier to predict response to neoadjuvant therapy in HER2‐positive and ER‐positive breast cancer patients: an explorative analysis from the NeoSphere trial

What is the real impact of estrogen receptor status on the prognosis and treatment of HER2-positive early breast cancer?

(2020) Mariana Brandão et al.   CLINICAL CANCER RESEARCH

Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade

(2020) Fara Brasó-Maristany et al.   Nature Communications

Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer

(2020) Aranzazu Fernandez-Martinez et al.   JOURNAL OF CLINICAL ONCOLOGY

The 41-gene classifier TRAR predicts response of HER2 positive breast cancer patients in the NeoALTTO study

(2019) Serena Di Cosimo et al.   EUROPEAN JOURNAL OF CANCER

Corrigendum: PAM50 Subtypes in Baseline and Residual Tumors Following Neoadjuvant Trastuzumab-Based Chemotherapy in HER2-Positive Breast Cancer: A Consecutive-Series From a Single Institution

(2019) Sonia Pernas et al.   Frontiers in Oncology

190PDResearch-based PAM50 predicts risk of relapse in residual disease after anti-HER2 therapies

(2018) G Bianchini et al.   ANNALS OF ONCOLOGY

Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer

(2018) Gunter von Minckwitz et al.   NEW ENGLAND JOURNAL OF MEDICINE

HER2-positive breast cancer is lost in translation: time for patient-centered research

(2017) Isabelle Gingras et al.   Nature Reviews Clinical Oncology

RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy

(2017) Debora Fumagalli et al.   JAMA Oncology

Predictive biomarkers in the treatment of HER2-positive breast cancer: an ongoing challenge

(2016) Tiziana Triulzi et al.   Future Oncology

5-year analysis of neoadjuvant pertuzumab and trastuzumab in patients with locally advanced, inflammatory, or early-stage HER2-positive breast cancer (NeoSphere): a multicentre, open-label, phase 2 randomised trial

(2016) Luca Gianni et al.   LANCET ONCOLOGY

Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial

(2015) G. Bianchini et al.   ANNALS OF ONCOLOGY

Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer

(2015) M. Callari et al.   CLINICAL CANCER RESEARCH

Natural and therapy-induced immunosurveillance in breast cancer

(2015) Guido Kroemer et al.   NATURE MEDICINE

Whole-transcriptome analysis links trastuzumab sensitivity of breast tumors to both HER2 dependence and immune cell infiltration

(2015) Tiziana Triulzi et al.   Oncotarget

First FDA Approval of Neoadjuvant Therapy for Breast Cancer: Pertuzumab for the Treatment of Patients with HER2-Positive Breast Cancer

(2014) L. Amiri-Kordestani et al.   CLINICAL CANCER RESEARCH

The immune system and response to HER2-targeted treatment in breast cancer

(2014) Giampaolo Bianchini et al.   LANCET ONCOLOGY

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

(2014) Gunter von Minckwitz et al.   LANCET ONCOLOGY

Human epidermal growth factor receptor 2 (HER2)-positive and hormone receptor-positive breast cancer: new insights into molecular interactions and clinical implications

(2013) F. Montemurro et al.   ANNALS OF ONCOLOGY

Bidirectional Crosstalk between the Estrogen Receptor and Human Epidermal Growth Factor Receptor 2 Signaling Pathways in Breast Cancer: Molecular Basis and Clinical Implications

(2013) Mario Giuliano et al.   Breast Care

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

(2012) José Baselga et al.   LANCET

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

(2011) Luca Gianni et al.   LANCET ONCOLOGY

Genomic Grade Index Is Associated With Response to Chemotherapy in Patients With Breast Cancer

(2009) Cornelia Liedtke et al.   JOURNAL OF CLINICAL ONCOLOGY

Understanding the Mechanisms Behind Trastuzumab Therapy for Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer

(2009) Neil L. Spector et al.   JOURNAL OF CLINICAL ONCOLOGY

Prognostic Utility of the 21-Gene Assay in Hormone Receptor–Positive Operable Breast Cancer Compared With Classical Clinicopathologic Features

(2008) Lori J. Goldstein et al.   JOURNAL OF CLINICAL ONCOLOGY